US Congress House Bill 1703 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Republican 2-0)
Status: Introduced on March 23 2017 - 25% progression, died in committee
Action: 2017-03-24 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Medical Product Communications Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to state that the intended use of a drug, biological product, or device shall be determined by the objective intent of the manufacturer and sponsor of such drug, biological product, or device, as demonstrated by statements contained in labeling, advertising, or analogous oral statements. The intended use of these medical products shall not be determined by actual or constructive knowledge of the manufacturer or sponsor that these products will be used in a manner that varies from the use approved for marketing. Additionally, the scientific exchange of information about these products shall not constitute labeling, advertising, or evidence of a new intended use. The bill sets forth the requirements for a scientific exchange.

Medical Product Communications Act of 2017

Rep. Morgan Griffith [R-VA]

Rep. Gus Bilirakis [R-FL]

Date	Chamber	Action
2017-03-24	House	Referred to the Subcommittee on Health.
2017-03-23	House	Referred to the House Committee on Energy and Commerce.
2017-03-23	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/115th-congress/house-bill/1703/all-info
Text	https://www.congress.gov/115/bills/hr1703/BILLS-115hr1703ih.pdf